We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Acting Antiretroviral Drug Therapy in Adolescents: Current Status and Future Prospects.
- Authors
Freij, Bishara J; Aldrich, Aileen M; Ogrin, Sara L; Olivero, Rosemary M
- Abstract
Approximately 50% of human immunodeficiency virus (HIV)-infected adolescents fail to achieve complete viral suppression, largely due to nonadherence to their antiretroviral drug regimens. Numerous personal, financial, and societal barriers contribute to nonadherence, which may lead to the development of HIV drug resistance. Long-acting antiretroviral drugs hold the promise of improved adherence because they remove the need for swallowing one or more pills daily. Cabotegravir (an integrase strand transfer inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) can now be intramuscularly co-administered to HIV-infected adolescents every 4–8 weeks if they are virologically suppressed and without resistance mutations to cabotegravir or rilpivirine. Adverse effects are few and non-severe. Widespread use of this complete antiretroviral therapy may be limited by drug costs, need for sites and skilled personnel who can administer the injections, and ethical challenges. Other long-acting medications and new antiretroviral therapy delivery systems are under active investigation and show great promise.
- Subjects
HIV infections; HIV integrase inhibitors; RILPIVIRINE; DRUG resistance; INTRAMUSCULAR injections; DRUGS; PATIENT compliance; ADOLESCENCE
- Publication
Journal of the Pediatric Infectious Diseases Society, 2023, Vol 12, Issue 1, p43
- ISSN
2048-7193
- Publication type
Article
- DOI
10.1093/jpids/piac134